Approval of 'Enaroy Tablets' Anemia Treatment for Chronic Kidney Disease Patients
[Asia Economy Reporter Jo In-kyung] The Ministry of Food and Drug Safety announced on the 18th that it has approved JW Pharmaceutical's 'Enaroy Tablet (Enarodustat),' developed as an anemia treatment for patients with kidney disease.
Enaroy Tablet is a medication that treats anemia occurring in adult patients with chronic kidney disease undergoing hemodialysis. It promotes red blood cell production by inhibiting prolyl hydroxylase, an enzyme that degrades the protein 'hypoxia-inducible factor,' which is responsible for producing red blood cells.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Bull Market End Signal? Securities Firm Warns: "Sell SK hynix 'At This Moment'"
- "Greater Impact on Women Than Men"... The 'Diet Trap' That Causes Sleepless Nights and Suffering
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
The Ministry of Food and Drug Safety stated that it will strive to ensure that treatments with confirmed safety and efficacy are supplied promptly, thereby expanding treatment opportunities for patients.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
